Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment

Cancer Gene Therapy volume 30, pages 932–935 (2023)Cite this article

Subjects

Abstract

Tumor heterogeneity affects diagnosis, prognosis and response to therapy. Heterogeneity is found in both normal and neoplastic human mammary gland. Indeed, luminal ER-negative cells can give rise to various phenotypes, including ER-negative and ER-positive mammary tumors. As a result, the tumor phenotype does not necessarily reflects the cell of origin of cancer. With regard to the ER status, heterogeneity can challenge endocrine therapies, where the elimination of responsive clones could lead to reduced treatment efficacy and tumor relapse through the expansion of the resistant clones. The aim of this study was to investigate breast tumor heterogeneity and its role in endocrine resistance onset. For this purpose, we used ER+ (T47D, CAMA1) and triple-negative breast cancer cell lines (TNBC; MDA-MB-231, HCC70), co-cultures using 2D and 3D models. Our results showed that ER status is modulated when ER+ cells are cultured in the presence of TNBC cells, leading to a different response to endocrine therapy, demonstrating that the response to treatment can be affected by the influence that different breast cancer cell types exert on each other. In addition, ER+ positive cells doubling time was modified after exposure to TNBC cell co-culturing. Further experiments are required to fully elucidate the molecular mechanism of these observations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Effects of MDA-MB-231 co-culture on CAMA1 cells response to tamoxifen.
Fig. 2: T47D cells reduce HCC70 response to treatment.

Similar content being viewed by others

References

  1. Altschuler SJ, Wu LF. Cellular heterogeneity: do differences make a difference? Cell. 2010;141:559–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Dagogo-Jack I, Shaw A. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94.

    Article  CAS  PubMed  Google Scholar 

  3. Tabassum D, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer. 2015;15:473–83.

    Article  CAS  PubMed  Google Scholar 

  4. Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183:1113–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Francis IM, Altemaimi RA, Al-Ayadhy B, Alath P, Jaragh M, Mothafar FJ, et al. Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management. J Cytol. 2019;36:94–100.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Colacino JA, Azizi E, Brooks MD, Harouaka R, Fouladdel S, McDermott SP, et al. Heterogeneity of human breast stem and progenitor cells as revealed by transcriptional profiling. Stem Cell Rep. 2018;10:1596–609.

    Article  CAS  Google Scholar 

  7. Koren S, Bentires-Alj M. Breast tumor heterogeneity: source of fitness, hurdle for therapy. Mol Cell. 2015;60:537–46.

    Article  CAS  PubMed  Google Scholar 

  8. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496–513.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Sonh JY, et al. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med. 2015;7:1104–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–28.

    Article  CAS  PubMed  Google Scholar 

  12. Lüönd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer. 2021;125:164–75.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V, et al. The structure-function relationship of oncogenic LMTK3. Sci Adv 2020;6:eabc3099.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gagliano T, Shah K, Gargani S, Lao L, Alsaleem M, Chen J, et al. PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression. J Clin Invest. 2020;130:3188–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bresciani G, Ditsiou A, Cilibrasi C, Vella V, Rea F, Schiavon M, et al. EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR? Endocr Connect. 2019;8:680–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gagliano T, Gentilin E, Tagliati F, Benfini K, Di Pasquale C, Feo C, et al. Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors. Biochem Pharm. 2015;98:639–48.

    Article  CAS  PubMed  Google Scholar 

  17. Stebbing J, Shah K, Lit LC, Gagliano T, Ditsiou A, Wang T, et al. LMTK3 confers chemo-resistance in breast cancer. Oncogene 2018;37:3113–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Karakas B, Aka Y, Giray A, Temel SG, Acikbas U, Basaga H. et al. Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells. Cell Death Discov. 2021;7:189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8:1095–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mills JN, Rutkovsky AC, Giordano A. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharm. 2018;41:59–65.

    Article  CAS  Google Scholar 

  21. Patani N, Martin LA. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol. 2014;382:683–94.

    Article  CAS  PubMed  Google Scholar 

  22. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010;120:293–308.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Udine, Udine, Italy

    Eleonora Malavasi & Teresa Gagliano

  2. School of Life Sciences, University of Sussex, Brighton, UK

    Georgios Giamas

Authors
  1. Eleonora Malavasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Georgios Giamas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teresa Gagliano
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TG and GG concived the idea. EM and TG performed the experiments. TG and EM wrote the manuscript. TG and GG supervised and directed the project.

Corresponding author

Correspondence to Teresa Gagliano.

Ethics declarations

Conflict of interest

Georgios Giamas is editor-in-chief of Cancer Gene Therapy. Teresa Gagliano is an associate editor of Cancer Gene Therapy. No other conflicts are declared. This manuscript went through a standard external peer review process and none of the authors were involved with this.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malavasi, E., Giamas, G. & Gagliano, T. Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment. Cancer Gene Ther 30, 932–935 (2023). https://doi.org/10.1038/s41417-023-00618-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-023-00618-x

This article is cited by

Search

Advanced search

Quick links